Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

146.23
-5.6000-3.69%
Post-market: 146.230.00000.00%19:55 EDT
Volume:2.82M
Turnover:414.38M
Market Cap:14.92B
PE:21.43
High:152.63
Open:152.63
Low:146.06
Close:151.83
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:2.71
T/O Rate:2.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:4.04
PE(LYR):31.31

Loading ...

A Look At Neurocrine Biosciences (NBIX) Valuation After CRENESSITY Phase 3 CAHtalyst Adult Results

Simply Wall St.
·
Apr 27

Needham Sticks to Its Buy Rating for Neurocrine (NBIX)

TIPRANKS
·
Apr 26

Transthera Sciences publishes 2025 annual report

Reuters
·
Apr 23

Neurocrine says crinecerfont cuts CAH glucocorticoid dose 38% at two years

Reuters
·
Apr 23

Neurocrine Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Apr 22

A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Persistence Data And Options Activity

Simply Wall St.
·
Apr 19

Neurocrine Biosciences publishes 2025 annual report

Reuters
·
Apr 16

Neurocrine Biosciences announces annual shareholder meeting

Reuters
·
Apr 16

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galmed Pharmaceuticals (GLMD), Neurocrine (NBIX) and Mesoblast (MESO)

TIPRANKS
·
Apr 15

Neurocrine schedules first-quarter results conference call and webcast

Reuters
·
Apr 15

Neurocrine claims analysis shows Ingrezza persistence tops Austedo XR in tardive dyskinesia

Reuters
·
Apr 14

Nxera partner Neurocrine starts Phase 2 trial of NBI-1117570 in schizophrenia

Reuters
·
Apr 13

Neurocrine Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Apr 10

Neurocrine Is Maintained at Buy by Citigroup

Dow Jones
·
Apr 08

Jefferies Reaffirms Their Buy Rating on Neurocrine (NBIX)

TIPRANKS
·
Apr 07

BUZZ-U.S. STOCKS ON THE MOVE -Virgin Galactic, Humana, Broadcom

Reuters
·
Apr 07

Neurocrine Biosciences Inc : Wedbush Raises Target Price to $166 From $151

THOMSON REUTERS
·
Apr 07

BUZZ-HC Wainwright lifts PT on Neurocrine after Soleno deal

Reuters
·
Apr 07

Neurocrine Biosciences Inc : H.c. Wainwright Raises Target Price to $215 From $192

THOMSON REUTERS
·
Apr 07